Physiological ligands of PPARs in inflammation and lipid homeostasis

Bibliography

• Kliewer SA, Forman BM, B Blumberg et al.: Differential expression and activation of a family of murine peroxisome proliferatoractivated receptors. Proc. Natl Acad. Sci. USA 91, 7355–7359 (1994)
   Google Scholar
• Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α,β andγ- in the adult rat. Endocrinology 137, 354–366 (1996)
   Google Scholar
• Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B: Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142, 4195–4202 (2001)
   Google Scholar
• Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20, 649–688 (1999)
   Google Scholar
• Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM: Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358, 771–774 (1992)
   Google Scholar
• Nolte RT, Wisely GB, Westin S et al.: Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor- . Nature 395, 137–143 (1998)
   Google Scholar
• Xu HE, Lambert MH, Montana VG et al.: Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell 3, 397–403 (1999)
   Google Scholar
• Xu HE, Lambert MH, Montana VG et al.: Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc. Natl Acad. Sci. USA 98, 13919–13924 (2001)
   Google Scholar
• Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W: From molecular action to physiological outputs: peroxisome proliferator-activated receptors (PPARs) are nuclear receptors at the crossroads of key cellular functions. Prog. Lipid Res. 45, 120–159 (2006)
   Google Scholar
• Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM: 15-Deoxy- 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR . Cell 83, 803–812 (1995)
   Google Scholar
• Kliewer SA, Sundseth SS, Jones SA et al.: Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors and . Proc. Natl Acad. Sci. USA 94, 4318–4323 (1997)
   Google Scholar
• Krey G, Braissant O, L'Horset F et al.: Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 11, 779–791 (1997)
   Google Scholar
• Forman BM, Chen J, Evans RM: Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors and . Proc. Natl Acad. Sci. USA 94, 4312–4317 (1997)
   Google Scholar
• Soares AF, Nosjean O, Cozzone D et al.: Covalent binding of 15-deoxy-Δ12,14- prostaglandin J2 to PPAR . Biochem. Biophys. Res. Commun. 337, 521–525 (2005).
   Google Scholar
• Peroxisome proliferator-activated receptor (PPARαcan bind covently with some of its natural ligands which opens up new perspectives to investigate the molecular basis for selective activities of PPARs.
   Google Scholar
• Shiraki T, Kamiya N, Shiki S, Kodama TS, Kakizuka A, Jingami H:α,β-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferatoractivated receptor gamma. J. Biol. Chem. 280, 14145–14153 (2005)
   Google Scholar
• Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Ann. Rev. Pharmacol. Toxicol. 38, 97–120 (1998)
   Google Scholar
• Brash AR: Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J. Biol. Chem. 274, 23679–23682 (1999)
   Google Scholar
• McMahon B, Mitchell S, Brady HR, Godson C: Lipoxins: revelations on resolution. Trends Pharmacol. Sci. 22, 391–395 (2001)
   Google Scholar
• Lee JL, Mukhtar H, Bickers DR, Kopelovich L, Athar M: Cyclooxygenases in the skin: pharmacological and toxicological implications. Toxicol. Appl. Pharmacol. 192, 294–306 (2003)
   Google Scholar
• Funk, CD: Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294, 1871–1875 (2001)
   Google Scholar
• Kostadinova R, Wahli W, Michalik L: PPARs in diseases: control mechanisms of inflammation. Current Med. Chem. 12, 2413–2446 (2005)
   Google Scholar
• Moraes LA, Piqueras L, Bishop-Bailey D: Peroxisome proliferator-activated receptors and inflammation. Pharmacol. Ther. (2005)
   Google Scholar
• Genolet R, Wahli W, Michalik L: PPARs as drug targets to modulate inflammatory responses? Curr. Drug Targets Inflamm. Allergy 3, 361–375 (2004)
   Google Scholar
• Yu K, Bayona W, Kallen CB et al.: Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem. 270, 23975–23983 (1995)
   Google Scholar
• Westergaard M, Henningsen J, Johansen C et al.: Expression and localization of peroxisome proliferator-activated receptors and nuclear factor B in normal and lesional psoriatic skin. J. Invest. Dermatol. 121, 1104–1117 (2003)
   Google Scholar
• Thuillier P, Brash AR, Kehrer JP et al.: Inhibition of peroxisome proliferatoractivated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors. Biochem. J. 366, 901–910 (2002)
   Google Scholar
• Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W: The PPAR -leukotriene B4 pathway to inflammation control. Nature 384, 39–43 (1996).
   Google Scholar
• First link between PPARαand inflammation and first demonstration of an involvement of PPARβand one of its endogenous ligand in the inflammatory response.
   Google Scholar
• Devchand PR, Hihi AK, Perroud M, Schleuning WD, Spiegelman BM, Wahli W: Chemical probes that differentially modulate peroxisome proliferator-activated receptor and BLTR, nuclear and cell surface receptors for leukotriene B(4). J. Biol. Chem. 274, 23341–23348 (1999)
   Google Scholar
• Lin Q, Ruuska SE, Shaw NS, Dong D, Noy N: Ligand selectivity of the peroxisome proliferator-activated receptor . Biochemistry 38, 185–190 (1999)
   Google Scholar
• Lewis DF, Jacobs MN, Dickins M, Lake BG: Molecular modelling of the peroxisome proliferator-activated receptor (PPAR alpha) from human, rat and mouse, based on homology with the human PPAR crystal structure. Toxicol. In Vitro 16, 275–280 (2002)
   Google Scholar
• Peters-Golden M, Brock TG: Intracellular compartmentalization of leukotriene synthesis: unexpected nuclear secrets. FEBS Lett. 487, 323–326 (2001)
   Google Scholar
• Michalik L, Desvergne B, Tan NS et al.: Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR) and PPAR mutant mice. J. Cell. Biol. 154, 799–814 (2001).
   Google Scholar
• First description of a role of PPARαand PPARin the promotion of wound healing.
   Google Scholar
• Staels B, Koenig W, Habib A et al.: Activation of human aortic smooth-muscle cells is inhibited by PPAR but not by PPAR activators. Nature 393, 790–793 (1998)
   Google Scholar
• Michalik L, Feige JN, Gelman L et al.: Selective expression of a dominant-negative form of peroxisome proliferator-activated receptor in keratinocytes leads to impaired epidermal healing. Mol. Endocrinol. 19, 2335–2348 (2005)
   Google Scholar
• Lo Verme J, Fu J, Astarita G et al.: The nuclear receptor peroxisome proliferatoractivated receptor- mediates the antiinflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 67, 15–19 (2005).
   Google Scholar
• Berdyshev EV, Schmid PC, Dong Z, Schmid HH: Stress-induced generation of N-acylethanolamines in mouse epidermal JB6 P+ cells. Biochem. J. 346 Pt 2, 369–74 (2000).
   Google Scholar
• Tan NS, Michalik L, Noy N et al.: Critical roles of PPAR / in keratinocyte response to inflammation. Genes Dev. 15, 3263–3277 (2001).
   Google Scholar
• Iversen L, Kragballe K: Arachidonic acid metabolism in skin health and disease. Prostaglandins Other Lipid Mediat. 63, 25–42 (2000).
   Google Scholar
• Fogh K, Kragballe K: Eicosanoids in inflammatory skin diseases. Prostaglandins Other Lipid Mediat. 63, 43–54 (2000).
   Google Scholar
• Lim H, Gupta RA, Ma WG et al.: Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPAR . Genes Dev. 13, 1561–1574 (1999).
   Google Scholar
• Demonstrates that prostaglandin (PG)I2 is a physiological ligand of PPARα.
   Google Scholar
• Helliwell RJ, Adams LF, Mitchell MD: Prostaglandin synthases: recent developments and a novel hypothesis. Prostaglandins Leukot. Essent. Fatty Acids 70, 101–113 (2004).
   Google Scholar
• Chawla A, Lee CH, Barak Y et al.: PPARdelta is a very low-density lipoprotein sensor in macrophages. Proc. Natl Acad. Sci. USA 100, 1268–1273 (2003).
   Google Scholar
• Lee CH, Chawla A, Urbiztondo N et al.: Transcriptional repression of atherogenic inflammation: modulation by PPAR . Science 302, 453–457 (2003).
   Google Scholar
• Zhao L, Funk CD: Lipoxygenase pathways in atherogenesis. Trends Cardiovasc. Med. 14, 191–195 (2004).
   Google Scholar
• Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM: A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor and promotes adipocyte differentiation. Cell 83, 813–819 (1995).
   Google Scholar
• The 15-deoxy-Δ12,14-prostaglandin (15d-PG)J2 is described here for the first time as PPARαligand.β
   Google Scholar
• Rossi A, Kapahi P, Natoli G et al.: Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I B kinase. Nature 403, 103–108 (2000).
   Google Scholar
• Hortelano S, Castrillo A, Alvarez AM, Bosca L: Contribution of cyclopentenone prostaglandins to the resolution of inflammation through the potentiation of apoptosis in activated macrophages. J. Immunol. 165, 6525–6531 (2000)
   Google Scholar
• Shibata T, Kondo M, Osawa T, Shibata N, Kobayashi M, Uchida K: 15-deoxy-Δ12,14- prostaglandin J2. A prostaglandin D2 metabolite generated during inflammatory processes. J. Biol. Chem. 277, 10459–10466 (2002)
   Google Scholar
• Bell-Parikh LC, Ide T, Lawson JA, McNamara P, Reilly M, FitzGerald GA: Biosynthesis of 15-deoxyΔ12,14-PGJ2 and the ligation of PPAR . J. Clin. Invest. 112, 945–955 (2003)
   Google Scholar
• Nosjean O, Boutin JA: Natural ligands of PPAR : are prostaglandin J(2) derivatives really playing the part? Cell Signal. 14, 573–583 (2002)
   Google Scholar
• Heydeck D, Thomas L, Schnurr K et al.: Interleukin-4 and -13 induce upregulation of the murine macrophage 12/15- lipoxygenase activity: evidence for the involvement of transcription factor STAT6. Blood 92, 2503–2510 (1998)
   Google Scholar
• Yoshimoto T, Takahashi Y: Arachidonate 12-lipoxygenases. Prostaglandins Other Lipid Mediat. 68–69, 245–262 (2002)
   Google Scholar
• Huang JT, Welch JS, Ricote M et al.: Interleukin-4-dependent production of PPAR- ligands in macrophages by 12/15- lipoxygenase. Nature 400, 378–382 (1999)
   Google Scholar
• Lusis AJ: Atherosclerosis. Nature 407, 233–241 (2000)
   Google Scholar
• Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM: Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR . Cell 93, 229–240 (1998)
   Google Scholar
• Davies SS, Pontsler AV, Marathe GK et al.: Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferatoractivated receptor ligands and agonists. J. Biol. Chem. 276, 16015–16023 (2001)
   Google Scholar
• Zhang Q, Southall MD, Mezsick SM et al.: Epidermal peroxisome proliferatoractivated receptor as a target for ultraviolet B radiation. J. Biol. Chem. 280, 73–79 (2005).
   Google Scholar
• Suggests that UVB-generated PPARαligands are produced via free radicalmediated nonenzymatic cleavage of endogenous glycerophosphocholines.
   Google Scholar
• McIntyre TM, Pontsler AV, Silva AR et al.: Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPAR agonist.Proc. Natl Acad. Sci. USA 100, 131–136 (2003)
   Google Scholar
• Moolenaar WH: Development of our current understanding of bioactive lysophospholipids. Ann. NY Acad. Sci. 905, 1–10 (2000)
   Google Scholar
• Aoki J: Mechanisms of lysophosphatidic acid production. Semin. Cell Dev. Biol. 15, 477–489 (2004)
   Google Scholar
• Liu Y, Zhu Y, Rannou F et al.: Laminar flow activates peroxisome proliferator-activated receptor- in vascular endothelial cells. Circulation 110, 1128–1133 (2004)
   Google Scholar
• Liu Y, Zhang Y, Schmelzer K et al.: The antiinflammatory effect of laminar flow: the role of PPAR , epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc. Natl Acad. Sci. USA 102(46), 16747–16752(2005)
   Google Scholar
• Schopfer FJ, Lin Y, Baker PR et al.: Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor ligand. Proc. Natl Acad. Sci. USA 102, 2340–2345 (2005)
   Google Scholar
• Baker PR, Lin Y, Schopfer FJ et al.: Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous PPAR-activated ligands. J. Biol. Chem. 280(51), 42464–42475 (2005)
   Google Scholar
• Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W: Peroxisome proliferator-activated receptor mediates the adaptive response to fasting. J. Clin. Invest. 103, 1489–1498 (1999)
   Google Scholar
• Leone TC, Weinheimer CJ, Kelly DP: A critical role for the peroxisome proliferatoractivated receptor (PPAR ) in the cellular fasting response: the PPAR -null mouse as a model of fatty acid oxidation disorders. Proc. Natl Acad. Sci. USA 96, 7473–7478 (1999)
   Google Scholar
• Hostetler HA, Petrescu AD, Kier AB, Schroeder F: Peroxisome proliferatoractivated receptor interacts with high affinity and is conformationally responsive to endogenous ligands. J. Biol. Chem. 280, 18667–17682 (2005).
   Google Scholar
• Direct fluorescence binding and displacement assays show that PPARαexhibits high affinity for saturated and unsaturated long chain fatty acyl-CoAs as well as unsaturated long chain-fatty acids.
   Google Scholar
• Yli-Jama P, Haugen TS, Rebnord HM, Ringstad J, Pedersen JI: Selective mobilisation of fatty acids from human adipose tissue. Eur. J. Intern. Med. 12, 107–115 (2001)
   Google Scholar
• Chakravarthy MV, Pan Z, Zhu Y et al.: "New" hepatic fat activates PPAR to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab. 1, 309–322 (2005)
   Google Scholar
• Patsouris D, Reddy JK, Muller M, Kersten S: Peroxisome proliferator-activated receptor mediates the effects of high-fat diet on hepatic gene expression. Endocrinology 147, 1508–1516 (2006)
   Google Scholar
• Fu J, Gaetani S, Oveisi F et al.: Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR- . Nature 425, 90–93 (2003)
   Google Scholar
• Matsusue K, Peters JM, Gonzalez FJ: PPAR / potentiates PPAR -stimulated adipocyte differentiation. FASEB J. 18, 1477–1479 (2004)
   Google Scholar
• Peters JM, Lee SS, Li W et al.: Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor ( ). Mol. Cell Biol. 20, 5119–5128 (2000)
   Google Scholar
• Oliver WR, Jr., Shenk JL, Snaith MR et al.: A selective peroxisome proliferatoractivated receptor agonist promotes reverse cholesterol transport. Proc. Natl Acad. Sci. USA 98, 5306–5311 (2001)
   Google Scholar
• Vosper H, Patel L, Graham TL et al.: The peroxisome proliferator-activated receptor promotes lipid accumulation in human macrophages. J. Biol. Chem. 276, 44258–44265 (2001)
   Google Scholar
• Akiyama TE, Lambert G, Nicol CJ et al.: Peroxisome proliferator-activated receptor beta/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet. J. Biol. Chem. 279, 20874–20881 (2004)
   Google Scholar
• Evans RM, Barish GD, Wang YX: PPARs and the complex journey to obesity. Nature Med. 10, 355–361 (2004)
   Google Scholar
• Holst D, Luquet S, Nogueira V, Kristiansen K, Leverve X, Grimaldi PA: Nutritional regulation and role of peroxisome proliferator-activated receptor in fatty acid catabolism in skeletal muscle. Biochim. Biophys. Acta 1633, 43–50 (2003)
   Google Scholar
• Tanaka T, Yamamoto J, Iwasaki S et al.: Activation of peroxisome proliferatoractivated receptor induces fatty acid - oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl Acad. Sci. USA 100, 15924–15929 (2003)
   Google Scholar
• Bedu E, Wahli W, Desvergne B: Peroxisome proliferator-activated receptor / as a therapeutic target for metabolic diseases. Expert Opin. Ther. Targets 9, 861–873 (2005)
   Google Scholar
• Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM: Transcriptional regulation of adipogenesis. Genes Dev. 14, 1293–1307 (2000)
   Google Scholar
• Rosen ED, Sarraf P, Troy AE et al.: PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 4, 611–617 (1999)
   Google Scholar
• Imai T, Takakuwa R, Marchand S et al.: Peroxisome proliferator-activated receptor is required in mature white and brown adipocytes for their survival in the mouse. Proc. Natl Acad. Sci. USA 101, 4543–4547 (2004)
   Google Scholar
• Camp HS, Chaudhry A, Leff T: A novel potent antagonist of peroxisome proliferator-activated receptor gamma blocks adipocyte differentiation but does not revert the phenotype of terminally differentiated adipocytes. Endocrinology 142, 3207–3213 (2001)
   Google Scholar
• Fu M, Sun T, Bookout AL et al.: A nuclear receptor atlas: 3T3-L1 adipogenesis. Mol. Endocrinol. 19, 2437–2450 (2005)
   Google Scholar
• Tzameli I, Fang H, Ollero M et al.: Regulated production of a peroxisome proliferator-activated receptor- ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes. J. Biol. Chem. 279, 36093–36102 (2004)
   Google Scholar
• McAdam BF, Mardini IA, Habib A et al.: Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J. Clin. Invest. 105, 1473–1482 (2000)
   Google Scholar
• Madsen L, Petersen RK, Sorensen MB et al.: Adipocyte differentiation of 3T3-L1 preadipocytes is dependent on lipoxygenase activity during initial stages of the differentiation process. Biochem. J. 375, 539–549 (2003)
   Google Scholar
• Rangwala SM, Lazar MA: The dawn of the SPPARMs? Sci. STKE 2002, PE9 (2002)
   Google Scholar
• Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89, 2548–2556 (2004)
   Google Scholar
• Feige JN, Gelman L, Tudor C, Engelborghs Y, Wahli W, Desvergne B: Fluorescence imaging reveals the nuclear behavior of peroxisome proliferatoractivated receptor/retinoid X receptor heterodimers in the absence and presence of ligand. J. Biol. Chem. 280, 17880–17890 (2005)
   Google Scholar
• Haunerland NH, Spener F: Fatty acidbinding proteins – insights from genetic manipulations. Prog. Lipid. Res. 43, 328–349 (2004)
   Google Scholar
• Coyle AT, O'Keeffe MB, Kinsella BT: 115-deoxyΔ12,14-prostaglandin J2 suppresses transcription by promoter 3 of the human thromboxane A2 receptor gene through peroxisome proliferator-activated receptor gamma in human erythroleukemia cells. FEBS J. 272, 4754–4773 (2005)
   Google Scholar
• Gelman L, Michalik L, Desvergne B, Wahli W: Kinase signaling cascades that modulate peroxisome proliferator-activated receptors. Curr. Opin. Cell Biol. 17, 216–222 (2005)
   Google Scholar
• Maggi A, Ciana P: Reporter mice and drug discovery and development. Nature Rev. Drug. Discov. 4, 249–255 (2005)
   Google Scholar
• Berger JP, Akiyama TE, Meinke PT: PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 26, 244–251 (2005)
   Google Scholar
• Patsouris D, Mandard S, Voshol PJ et al.: PPAR governs glycerol metabolism. J. Clin. Invest. 114, 94–103 (2004).
   Google Scholar